Cellebrite (CLBTW) schedules 2025 Annual General Meeting and files proxy materials

Rhea-AI Filing Summary

Cellebrite DI Ltd. is calling its Annual General Meeting of Shareholders for September 19, 2025, at 4:00 p.m. Israel time at its headquarters in Petah Tikva, Israel. The company is providing a notice and proxy statement, along with a proxy card, so shareholders can review the agenda and vote on the items to be considered at the meeting. The materials furnished with this report are also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3, linking the meeting-related disclosures to its U.S. securities offerings framework.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025.

Commission File Number 001-40772

Cellebrite DI Ltd.

(Translation of registrant’s name into English)

94 Shlomo Shmelzer Road

Petah Tikva 4970602, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On August 15, 2025, Cellebrite DI Ltd. (the “Registrant” or “Company”) announced that the Company’s Annual General Meeting of its Shareholders (the “Annual General Meeting”) will be held on Friday, September 19, 2025, at 4:00 p.m. Israel time, at the Company’s offices at 94 Shlomo Shmelzer Road, Petah Tikva 4970602, Israel. In connection with the Annual General Meeting, the Company hereby furnishes the following documents:

i. Notice and Proxy Statement with respect to the Annual General Meeting describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting; and

ii. A Proxy Card whereby holders of Company’s shares may vote at the meeting without attending in person.

This Report on Form 6-K, and the exhibits hereto, excluding the letter from the Company’s Chief Executive Officer, are incorporated by reference into the Registrant’s registration statements on Form S-8 (File Nos. 333-260878 and 333-278130) filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2021 and March 21, 2024, respectively, and Form F-3 (File No. 333-259826) filed with the SEC on September 13, 2022. 

1 

Exhibit Index

Exhibit		Description
99.1		Notice and Proxy Statement for the Company’s Annual General Meeting of Shareholders to be held on September 19, 2025.
99.2		Proxy Card for the Company’s Annual General Meeting of Shareholders to be held on September 19, 2025.

2 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellebrite DI Ltd.
August 15, 2025	By:	/s/ Ayala Berler Shapira
		Ayala Berler Shapira, Adv.
		General Counsel

3 

FAQ

When is Cellebrite (CLBTW) holding its 2025 Annual General Meeting?

The 2025 Annual General Meeting of Shareholders is scheduled for September 19, 2025, at 4:00 p.m. Israel time.

Where will Cellebrite’s 2025 Annual General Meeting take place?

The meeting will be held at Cellebrite DI Ltd.’s offices, 94 Shlomo Shmelzer Road, Petah Tikva 4970602, Israel.

What documents did Cellebrite (CLBTW) furnish in connection with the 2025 Annual General Meeting?

Cellebrite furnished a Notice and Proxy Statement for the Annual General Meeting and a Proxy Card for shareholders.

How are the Annual General Meeting materials linked to Cellebrite’s U.S. registration statements?

This report on Form 6-K and its exhibits, excluding the CEO’s letter, are incorporated by reference into Cellebrite’s Form S-8 registration statements (File Nos. 333-260878 and 333-278130) and its Form F-3 registration statement (File No. 333-259826).

Which SEC annual report form does Cellebrite DI Ltd. use?

Cellebrite files its annual reports under cover of Form 20-F as a foreign private issuer.

Who signed the Form 6-K for Cellebrite’s 2025 Annual General Meeting?

The report was signed on behalf of Cellebrite DI Ltd. by Ayala Berler Shapira, General Counsel.